- Home
- OXBR vs BIAF Comparison
OXBR vs BIAF Comparison
Compare OXBR & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXBR
- BIAF
- Stock Information
- Founded
- OXBR 2013
- BIAF 2014
- Country
- OXBR Cayman Islands
- BIAF United States
- Employees
- OXBR N/A
- BIAF N/A
- Industry
- OXBR Property-Casualty Insurers
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- OXBR Finance
- BIAF Health Care
- Exchange
- OXBR Nasdaq
- BIAF Nasdaq
- Market Cap
- OXBR 11.3M
- BIAF 12.2M
- IPO Year
- OXBR 2014
- BIAF 2022
- Fundamental
- Price
- OXBR $1.39
- BIAF $0.50
- Analyst Decision
- OXBR
- BIAF Hold
- Analyst Count
- OXBR 0
- BIAF 1
- Target Price
- OXBR N/A
- BIAF N/A
- AVG Volume (30 Days)
- OXBR 25.9K
- BIAF 28.5M
- Earning Date
- OXBR 05-08-2025
- BIAF 05-14-2025
- Dividend Yield
- OXBR N/A
- BIAF N/A
- EPS Growth
- OXBR N/A
- BIAF N/A
- EPS
- OXBR N/A
- BIAF N/A
- Revenue
- OXBR $546,000.00
- BIAF $9,362,022.00
- Revenue This Year
- OXBR N/A
- BIAF N/A
- Revenue Next Year
- OXBR N/A
- BIAF $19.99
- P/E Ratio
- OXBR N/A
- BIAF N/A
- Revenue Growth
- OXBR N/A
- BIAF 269.68
- 52 Week Low
- OXBR $1.01
- BIAF $0.24
- 52 Week High
- OXBR $5.81
- BIAF $3.16
- Technical
- Relative Strength Index (RSI)
- OXBR 22.94
- BIAF 48.20
- Support Level
- OXBR $1.42
- BIAF $0.46
- Resistance Level
- OXBR $1.56
- BIAF $0.54
- Average True Range (ATR)
- OXBR 0.16
- BIAF 0.10
- MACD
- OXBR 0.05
- BIAF -0.01
- Stochastic Oscillator
- OXBR 7.48
- BIAF 10.82
About OXBR Oxbridge Re Holdings Limited
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.